to Expand Cordis' Cardiovascular Product Offerings in Asia Pacific
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다
(SINGAPORE, Nov. 2, 2016 PRNewswire=연합뉴스) Cardinal Health has entered into two new distribution agreements that will enable Cordis, its interventional vascular business, to expand its cardiovascular portfolio in Asia Pacific.
Cardinal Health has expanded its current distribution agreement with Biosensors, which enables Cordis to be the exclusive distributor for Biosensors' coronary interventional products in Japan. The company also signed a distribution agreement with Kaneka that enables Cordis to distribute Kaneka's percutaneous transluminal coronary angioplasty (PTCA) balloon catheters in Europe, the Middle East and Africa (EMEA), Latin America (LATAM) and Asia Pacific, including China, Japan, Korea, Australia and New Zealand. These agreements further strengthen Cordis' robust product offering in the interventional cardiology space and overall position in the Asia Pacific region.
"This is a pivotal step in our ambition to expand Cordis' strong and diversified portfolio of products within the cardiovascular space in Asia Pacific," said Patrick Holt, president, Cardinal Health Medical Products Asia Pacific. "We are committed to delivering solutions aligned with government priorities and patient needs to ultimately make a significant contribution to this dynamic region."
Cordis will exclusively distribute Biosensors' BMX-J™ drug-eluting stent (DES) system and bp22-4D PTCA balloon in Japan. This agreement builds on the existing distribution agreement with Biosensors announced in May 2016, which marked Cordis' return to the DES market in select countries in EMEA, Australia and New Zealand. Biosensors' robust portfolio of products further supports the treatment of patients undergoing percutaneous coronary intervention (PCI). PCI is a nonsurgical procedure that often uses a catheter to place a stent to open blocked coronary arteries.
In the distribution agreement with Kaneka, Cordis will distribute Kaneka's comprehensive portfolio of high-quality, semi- and non-compliant workhorse PTCA balloon catheters. In Japan, Korea, Australia and New Zealand, Cordis will distribute versions of Kaneka's PTCA balloon catheters under the names of NEON™ and NEON™ NC. In China, Cordis will be the sole distributor of Ikazuchi Rev and Fortis II, under Kaneka's brand. Upon their approval* in China, Cordis will also distribute Ikazuchi Zero and Raiden 3. Kaneka's workhorse PTCA balloon catheters have a low-entry profile and new hydrophilic coating that facilitate access to calcified lesions or lesions that require higher crossability.
Despite the majority of premature deaths from the disease being preventable, cardiovascular disease accounts for about 17.5 million deaths annually, an estimated 31% of all deaths worldwide.[1] Asia Pacific is a growing market for interventional cardiology. It is expected to grow at a CAGR of 4.8% from 2014 to 2022, at a much higher rate than the expected CAGR of 2.9% for the global market over the same duration. The global market for interventional cardiology devices is expected to be valued at US$11.16 billion by the end of 2022.[2]
About Cardinal Health
Cardinal Health, Inc., a global health services and products company, brings scaled solutions that help our customers thrive in a changing world. We improve the cost effectiveness of healthcare through solutions that improve the efficiency of the supply chain; optimize the process and performance of healthcare; provide clinically proven, daily-use medical products and pharmaceuticals; and connect patients, providers, payers, pharmacists, and manufacturers for seamless care coordination and better patient management. Backed by nearly 100 years of experience, we rank among the top 50 on the Fortune 500 and among the Fortune Global 100. We support our partners with more than 37,000 employees in nearly 60 countries worldwide. For more information, visit cardinalhealth.com and @CardinalHealth [https://twitter.com/cardinalhealth ] on Twitter.
*Ikazuchi Zero and Raiden 3 are not currently approved or commercially available today in China.
[1] http://www.who.int/cardiovascular_diseases/en/
[2] http://www.transparencymarketresearch.com/interventional-cardiology-devices.html
Media:
Jasmine Chng,
jasmine.chng@cardinalhealth.com
+65-6230-2569
Logo - http://photos.prnasia.com/prnh/20161027/8521606855LOGO
Source: Cardinal Health
(끝)
출처 : PRNewswire 보도자료
본 보도자료는 연합뉴스의 편집방향과 무관하며 모든 책임은 제공자에 있습니다.
